Posted by Michael Wonder on 30 Sep 2022
Schedule of Pharmaceutical Benefits - 1 October 2022
1 October 2022 - The October 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The October issue of the Schedule includes a number of major new/revised listings:
- Avelumab (Bavencio) - new indication
- Cedazuridine with decitabine (Inqovi) - new combination product
- Enzalutamide (Xtandi) - new indication
- Fremanezemab (Ajovy) - new formulation
- Mecasermin (Increlix) - new medicine
- Pembrolizumab (Keytruda) - new indication
- Nivolumab (Opdivo) - new indication
- Somatrogon (Ngenla) - new medicine
- Trientine dihydrochloride (Trientine Waymade) - new medicine
